D.A. Davidson & CO. Boosts Position in DexCom, Inc. $DXCM

D.A. Davidson & CO. boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.7% in the second quarter, Holdings Channel reports. The fund owned 29,427 shares of the medical device company’s stock after purchasing an additional 3,315 shares during the quarter. D.A. Davidson & CO.’s holdings in DexCom were worth $2,569,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Golden State Wealth Management LLC increased its position in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in DexCom in the first quarter worth about $27,000. Anderson Financial Strategies LLC purchased a new stake in DexCom in the first quarter worth about $37,000. Private Trust Co. NA increased its position in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares in the last quarter. Finally, Horizon Financial Services LLC bought a new position in shares of DexCom in the first quarter worth about $56,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock valued at $564,733 in the last ninety days. Corporate insiders own 0.32% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $70.33 on Friday. The stock has a 50 day moving average of $72.37 and a 200 day moving average of $77.90. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a market cap of $27.58 billion, a PE ratio of 48.84, a PEG ratio of 1.48 and a beta of 1.47. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The firm’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Argus assumed coverage on DexCom in a research note on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. Morgan Stanley upped their price objective on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Finally, William Blair raised DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.19.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.